SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to President Trump's aggressive social media rhetoric regarding the escalating conflict with Iran, including threats to target civilian infrastructure. Discussions are dominated by intense political polarization, with many users debating the effectiveness of his foreign policy, the accuracy of reported military mission outcomes, and the broader economic implications for oil markets and inflation.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing heightened volatility and community skepticism as market participants debate the credibility of shifting geopolitical deadlines regarding the conflict in Iran and the Strait of Hormuz. Investors are actively questioning whether recent price action is a product of fundamental market strength or artificial manipulation driven by speculative trading and inconsistent executive messaging.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The market is reacting to headlines about potential ceasefire negotiations, leading to significant volatility as participants debate whether these reports are genuine developments or part of a broader cycle of headline-driven manipulation. The community remains deeply divided, with many traders expressing skepticism about the credibility of the reports and questioning if the ongoing geopolitical tensions are being used to influence short-term price action.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending due to intensifying speculation regarding a potential buyout or major partnership, fueled by activist pressure from Shah Capital to unlock shareholder value. While the company's core technology remains a focal point of community discussion, investor frustration is high due to ongoing volatility and silence from leadership regarding the status of key assets like the CIC vaccine.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense trading activity as investors weigh the semiconductor sector's high valuation against geopolitical tensions and concerns over a potential AI bubble. Community discussion is split between those aggressively scalping the volatility for quick gains and bears positioning for a major market correction, with many traders closely monitoring semiconductor earnings and macroeconomic data as potential catalysts for a breakdown.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is currently trending due to its innovative WVE-007 obesity program, which aims to provide a differentiated 'muscle-sparing' alternative to traditional GLP-1 therapies through RNA interference. Investors and the biotech community are actively discussing the company's potential as a prime acquisition target as major pharmaceutical firms scramble to secure next-generation obesity assets before looming patent cliffs.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, triggering analyst price target hikes and intense speculation regarding its long-term commercial potential. Investors are actively discussing the stock's massive overnight gains and potential for a short squeeze, while debating whether the current valuation fully reflects the drug's blockbuster prospects.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by escalating geopolitical tensions in the Middle East, specifically the blockage of the Strait of Hormuz and reports of strikes on critical energy infrastructure. Investors are closely monitoring a looming policy deadline and conflicting headlines regarding potential ceasefires, fueling a debate among the community between positioning for a structural oil supply crisis or betting on a rapid de-escalation.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

iShares Semiconductor ETF (SOXX) is currently a focal point for intense debate, as investors weigh sustained demand for AI-driven infrastructure against technical indicators suggesting the sector may be overextended. The community remains deeply divided, with bulls pointing to robust long-term growth and consistent dip-buying as signs of a 'buy the dip' market, while skeptics warn of a speculative bubble, citing concerns over high valuations, trade policy impacts, and potential mean reversion.

Direxion Shares ETF Trust - Direxion Small Cap Bear 3X ETF

Direxion Daily Small Cap Bear 3X Shares

The community is actively trading TZA to hedge against small-cap volatility and shifting economic expectations, with many users debating the sustainability of recent rallies and potential market downturns. Discussions heavily emphasize using inverse ETFs like TZA as a strategic tool to capitalize on market dips, while others express caution regarding the long-term decay risks inherent in holding leveraged products.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS

Aberdeen Group plc boosted its position in Oculis Holding AG (NASDAQ:OCS - Free Report) by 39.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund...

Oculis (NASDAQ:OCS) Trading Up 9.2%  - Time to Buy?

Oculis (NASDAQ:OCS) Shares Up 9.2% - Should You Buy...

Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 490,094 shares, a drop of 21.5% from the February 26th total of 623,971 shares. Based on an average trading volume of...

Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given...

Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS

Syquant Capital Sas purchased a new position in Oculis Holding AG (NASDAQ:OCS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 192,722 shares of the company's stock, valued at appro...

Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 623,971 shares, an...

Oculis (NASDAQ:OCS) Sees Large Volume Increase - Here's What Happened

Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume - Here's What Happened...

Oculis (NASDAQ:OCS) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered Oculis from a "hold" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Weighs in on Oculis' Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2026 earnings estimates for Oculis in a research report issued to clients and investors on...

Lifesci Capital Estimates Oculis' Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Lifesci Capital decreased their Q1 2026 earnings per share estimates for shares of Oculis in a report released on Wednesday, March 4th. Lifesci Capital...

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Oculis Holding AG

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

OCS
Oculis Holding AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OCS News

OCSOculis Holding AG